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significantly increased from 18% to 25% with carvedilol and bisoprolol versus meto-
prolol tartrate. Our primary findings were consistent through various sensitivity 
analyses. ConClusions: We suggest that there is no evidence of a differential 
effect of β -blockers on mortality in older patients with HF, but the agent selected 
may have an impact on the rate of HF readmissions.
PCV57
Mortality trends in CardioVasCular disease: a new Model to 
Visualise the Contribution of sPeCifiC diseases, Cohort effeCts and 
Coding Changes to oVerall Mortality iMProVeMent
Martin C, Martin A
Crystallise Ltd., London, UK
objeCtives: Identifying the drivers of trends in mortality for disease classes is 
challenging. We used the Requiem model to visualise trends by gender and age in 
3-D format to identify cohort effects, impacts of interventions and mortality coding 
changes in specific cardiovascular diseases (CVD). Methods: The Requiem model 
analysed and smoothed ONS mortality statistics for England and Wales from 1970 
to 2013 by single year of age and gender. Disease codes were mapped at 4-digit 
level from ICD-8 to ICD-10 by medical modellers. An analysis was run for all CVD 
and individual diseases within that category. Outputs were displayed in multiple 
formats, including 3-D images of central mortality and deaths by age over time, 
and heat maps of absolute mortality improvement per disease and the component 
each disease contributed to all-cause mortality trends. Results: CVD mortality 
has declined by up to 8% per year in England and Wales, especially in the “golden 
cohort” born in the 1930s, as shown clearly in the heat maps. Mortality rates from 
ischaemic stroke have fallen precipitously by up to 10% per year in both genders, 
especially in the 80+ age group, as shown in the 3-D charts. This contributed up to 
0.4% absolute improvement in all-cause mortality prior to 1990. Mortality improve-
ment from myocardial infarction was up to 20% per year in both genders aged 
40 to 80, especially in the mid-1980s to 1990s, contributing up to 2% in absolute 
improvement in all-cause mortality in men in the mid-1980s and 1% in women in 
the early 1990s. ConClusions: The Requiem model 3-D visualisation shows the 
substantial improvement in mortality from CVD and all causes was largely driven by 
improvements in ischaemic stroke and MI in the golden cohort. In future years, as 
this cohort eventually dies, mortality improvement rates in CVD are likely to decline.
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siMPson’s Paradox: why sMoking reduCes the risk of dying of 
CardioVasCular disease
Martin A, Martin C
Crystallise Ltd., London, UK
objeCtives: To use a stochastic all-cause, cause of death mortality model to deter-
mine the risk of cardiovascular (CVD) mortality in smokers compared with non-
smokers in the UK allowing for competing causes of death. Methods: The Sonata 
Vivo model adjusts population baseline mortality for known risk factors to calculate 
the mean age of death and most likely causes of death for an individual, and has 
been validated against long-term cohorts in the UK and USA. We used the model to 
calculate the likely outcomes for a 50 year-old male who smokes no, 10 or 20 ciga-
rettes a day, with population average values for blood pressure, body-mass index, 
cholesterol and alcohol consumption. Results: The mean ages of death were 82.7 
years for the non-smoker, 78.7 years for a 10/day and 76.1 years for a 20/day smoker. 
At each year of life, smokers had a higher mortality from CVD than non-smokers. 
However, overall, there were fewer CVD deaths in smokers than non-smokers. This is 
an example of Simpson’s paradox, where an association between factors at a popu-
lation level may be the opposite for each subgroup in the population. Smokers have 
increased mortality from cancer and respiratory disease, and on average die of these 
at a younger age than those who eventually die of CVD. Smokers also have fewer 
years of life than non-smokers in which CVD deaths can occur. ConClusions: 
Smoking increases the risk of many diseases, which have their greatest impact at 
different ages. Smokers have lower overall risks of CVD death as they are more likely 
than non-smokers to have died of cancer before the peak age for CVD deaths. The 
real-world effect of interventions for smoking-related diseases will be influenced 
by this impact of competing causes of death.
CardioVasCular disorders – Cost studies
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budget iMPaCt Model (biM) of riVaroxaban in CoMParison 
with enoxaParin Plus warfarin in the treatMent of Venous 
throMboeMbolisM (Vte) under the PersPeCtiVe of the PriVate health 
systeM
Piedade A1, Paladini L1, Tobaruella F2, Nakada C2
1Evidências - Kantar Health, Campinas, Brazil, 2Bayer Healthcare, São Paulo, Brazil
objeCtives: Venous thromboembolism(VTE) which comprises deep vein 
thrombosis(DVT) and pulmonary embolism(PE) is associated with a significant health-
care burden. Currently, standard of care is parenteral low molecular weight heparin 
(enoxaparin) plus warfarin. Rivaroxaban is an oral anticoagulant that doesn’t require 
dose adjustment or routine coagulation monitoring, bringing an important advan-
tage for VTE treatment. The EINSTEIN clinical program of rivaroxaban showed that, 
overall, hospitalized patients who received initial treatment with rivaroxaban for DVT 
and PE had a significantly shorter length of stay compared to patients who received 
enoxaparin/VKA. Therefore, the aim of this study was to estimate the budget impact 
of rivaroxaban treatment for VTE in comparison with current practice. Methods: 
The BIM was developed with a 1-year time horizon. Eligible patients were estimated 
for the entire private health system population and for single health plan according to 
three profiles (big, medium and small size). Epidemiology data, drug costs and adverse 
events information were obtained from literature. Resource utilization was captured 
from literature and validated by an expert panel. Total costs of hospitalization and 
14.5); ACS 12-24 months, 7.0 (95% CI 5.8-8.2); ischaemic stroke, 7.8 (95% CI 7.2-8.5); 
other CHD, 5.0 (95% CI 4.9-5.1); PAD, 6.7 (95% CI 6.4-7.1); diabetes without CVD, 1.9 
(95% CI 1.9-1.9); CKD without CVD, 6.4 (95% CI 5.9-6.9). ConClusions: This study 
suggests that CV event rates continue to remain high in the UK general popula-
tion with CVD or CKD. Patients who experienced an ACS event during the past 12 
months and those with a history of ischaemic stroke are at a particularly elevated 
risk for recurrent events.
PCV54
a CoMParison of ClassifiCation and regression trees and logistiC 
regression for PrediCting death of older long-terM Care users in 
JaPan
Lin H, Sasaki N, Kunisawa S, Otsubo T, Imanaka Y
Kyoto University, Kyoto, Japan
objeCtives: Long-Term Care (LTC) service users with dementia show higher 
expenditure and association of care-needs level (CNL) deterioration. The aim of 
this study was to determine risk factors that are associated with death among 
elderly LTC service users in Japan. Methods: In a retrospective cohort study, we 
extracted data from all subjects who used LTC services with CNL ranging from 1 
to 5 in 2010 in Kyoto prefecture, Japan. Our sample consisted of 50,268 adults aged 
65 years and above in 2010 and who had given consent to linkage of their National 
Healthcare Insurance data with corresponding LTC insurance claims data. Dementia 
and death were defined according to the corresponding ICD-10 code. Logistic regres-
sion (LR) analysis was used to identify factors associated with death in June 2011. 
Furthermore, we developed and pruned a supervised learning approach using non-
parametric Classification and Regression Tree (CART) and Random Forest (RF), the 
algorithms of machine learning, to create risk factors for death. In order to avoid 
model over fitting, we did our sampling by 1 to 1 ratio. Finally, our samples consisted 
of 12,070 adults enrolled and set 70% as training dataset, 15% as testing dataset, 
and 15% as validation dataset. Results: The factors associated with death were 
hospitalization more than 30 days in one year, older age, the male sex, and higher 
CNL, facility care services/ home care services use, and new dementia diagnosis 
with an area under the curve (AUC) of 0.782. Similar results were observed in the 
supervised learning approach, which including CART and RF for death with an AUC 
of 0.7333 and 0.7623, respectively. ConClusions: When applied prudently, both 
LR and CART are suitable for the analysis of death prediction, and more research 
is required to investigate the factors that are related to long-term hospitalization 
among elderly.
PCV55
PrediCtion Model for funCtional status at disCharge following 
rhabilitation after intraCerebral heMorrhage
Kim S1, Shin J2, Kim S3, Hahn S1
1Seoul National University College of Medicine, Seoul, South Korea, 2National Rehabilitation 
Center, Ministry of Health and Welfare, Seoul, South Korea, 3Systems Biomedical Informatics 
National Core Research Center, Seoul, South Korea
objeCtives: Few studies examined the course of functional recovery following 
rehabilitation in patients after intracerebral hemorrhage (ICH). The prediction of 
progressive increments in functional status is important for appropriate treatment 
planning and for setting rehabilitation goals. The aim of this study was to develop 
and validate a prognostication model to predict the functional status at discharge 
for ICH patients using a retrospective cohort data in the Korea. Methods: Data 
were collected on electronic medical record (EMR) referrals and brain computed 
tomography (CT) images from the National Rehabilitation Center (NRC) in Korea. 
Functional level was measured using the modified bathel index (MBI), recorded at 
admission and discharge. Factors considered for predictors associated with the MBI 
total score at discharge included patients’ clinical and imaging variables (ICH loca-
tion, ICH volume, mass effect due to hemorrhage etc) at the admission. Results: 
Five hundred twenty six patients aged 13 years or older (mean age: 57.2 years) who 
were discharged between November 15, 2006 and April 24, 2015, from NRC were 
retrospectively followed. Predictors of the total discharge MBI score included stand-
ing balance, cognitive function measured by the total score of Mini-Mental State 
Examination (MMSE), functional ambulation categories, muscle strength of left hip 
flexor, muscle strength of right knee extensor, presence of pneumonia, spasticity of 
right lower extremity, intraventricular hemorrhage score, abnormality of pain sense, 
aphasia, hemorrhage of brainstem, intracerebral hemorrhage volume, longitudinal 
sitting balance, mass effect due to hemorrhage. The adequacy of prediction was as 
measured by adjusted R2= 0.8013. ConClusions: The functional status prediction 
model performed well. Further studies should be planned to evaluate whether the 
model can be of practical use to physicians when attempting to set up an appropri-
ate rehabilitation schedule at the patients’ admission.
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Bezard F
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objeCtives: To compare the effectiveness of ß-blockers for older patients follow-
ing a primary hospital admission for HF. Methods: We conducted a cohort study 
using Quebec administrative databases to identify patients who were prescribed the 
ß-blockers, carvedilol, bisoprolol or metoprolol tartrate after the diagnosis of HF. We 
characterize the patients by the type of ß-blocker prescribed at discharge of their 
first HF hospitalization. To control for differences among patient characteristics, a 
multivariate Cox proportional hazards model was used to compare the combined 
primary endpoint of all-cause mortality and HF readmission, its components, and 
cardiovascular mortality. Results: Of the 3609 patients with HF with a median fol-
low-up of 3.0 years, the crude annual mortality was 16.5% with metoprolol tartrate, 
15.7% with carvedilol, and 17.7% with bisoprolol. After controlling for covariates, 
we found that carvedilol (HR 0.94; 0.80-1.09) and bisoprolol (HR 1.05; 0.94-1.17) were 
not superior to metoprolol tartrate in improving survival. HF readmission rate was 
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tive of the model was to assess the change of disease progression due to higher 
percentage of treated patients with iv iron and subsequently the impact on the 
health care costs. Disease progression was modelled by using a sequential Markov 
model with monthly transitions of NYHA health states of the cohort. The model 
takes into account direct costs (NYHA, hospital, outpatient and iron therapy) from 
2014 and data from a systematic literature review (RCT, cohort studies and clinical 
guidelines). Results: The result of the BIA shows that an increased use of iv iron 
therapy (based on a iv iron treatment scenario- treated patients +20% and iv iron 
treated patients +10%) in Austria would lead to a positive budget impact. By treating 
ID with FCM saving effects are achieved through reduced cost in the CHF manage-
ment (NYHA class shift) and reduced hospitalizations. The overall saving effect was 
calculated as € 225,115 in 2014 to € 684,443 in the 3rd year. ConClusions: Iv iron 
therapy with FCM in iron deficient CHF patients can be associated with substantial 
cost savings based on reduced hospitalisations and improved CHF functional class 
(NYHA).
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an assesMent of enoxaParine benefit on healthCare budget in sPain
Delgado M1, Restovic G2, Planellas L2, Rubio M1, Miñarro C3
1Sanofi, Barcelona, Spain, 2IMS Health, Barcelona, Spain, 3IMS Health, Madrid, Spain
objeCtives: Assessing the benefit of enoxaparine on healthcare budget for the 
prophylaxis of the venous thromboembolism disease (VTE) and the treatment of 
deep vein thrombosis (DVT) with and without pulmonary embolism (EP) in Spain 
and its Autonomous Communities (ACs). Methods: Prophylaxis patients were clas-
sified as moderate or high-risk according to the surgery type. The budget impact was 
estimated by comparing the cost in a scenario where 100% of the market is covered 
with enoxaparine from a scenario with only bemiparine. An additional analysis was 
performed considering the current treatment setting with all heparins available 
in the market versus a projected scenario where all patients receive enoxaparine. 
Cost estimation was based on real sales per product and pack over a year (March 
2014 to February 2015) obtained from IMS Health database (Dataview), and on the 
retail price plus the value-added tax in 2015, discounting the deductions according 
to Royal Decrees. Results: In the scenario comparing enoxaparine to bemiparine, 
the administration of enoxaparine for VTE prophylaxis would lead to a cost saving 
for the national health system of 10.138.123€ for high-risk patients and 744.684€ 
for moderate risk patients, depending on the AC savings range from 22.524€ to 
1.952.898€ and from 2.314€ to 162.328€ in patients with high and moderate risk, 
respectively. In the treatment of DVT at national level the average savings come to 
8.125.273€ , and at regional level these vary between 21.969€ and 1.671.395€ . Savings 
obtained when comparing a scenario with only enoxaparine versus the current 
setting with all heparins come to 3.368.555€ and 9.813.120€ for prophylaxis of VTE 
and treatment of DVT, respectively, at national level. ConClusions: Broader use of 
enoxaparine for the prophylaxis of VTE and treatment of DVT with and without PE in 
Spain and its ACs would lead to an economic benefit for the Spanish health system.
PCV64
Cost saVings by the use of beMiParin in the treatMent of Patients 
with Venous throMboeMbolisM in sPain
Pinyol C1, Navarro B2, Fernández-Lomana JM2, Gutiérrez C2
1INNOVA Strategic Consulting, Terrassa (Barcelona), Spain, 2Laboratorios Farmacéuticos Rovi 
S.A., Madrid, Spain
objeCtives: Venous thromboembolism (VTE) is the third most common cause of 
death from cardiovascular disease after acute MI and stroke. Initial treatment of 
VTE using heparin or LMWH has been recommended by different international 
guidelines. The aim of this study was to analyze the economic impact that could 
represent the use of bemiparin compared with the conventional treatment in 
Spain. Methods: An interactive Excel model for 3 years was developed using 
data obtained through a published literature review, including treatment costs and 
complications costs, for the Spanish National Health System. Public prices + VAT 
of bemiparin and enoxaparin were used. We consider a conservative co-payment 
of 40% for all patients. Patients were treated with LMWH for 7 days. Percentages 
and costs of complications were obtain from the literature. Three scenarios were 
designed: In the first scenario, patients were treated with bemiparin or enoxaparin 
using the current marked share, in the second 100% of patients were treated with 
bemiparin and, in the third scenario, 100% of patients were treated with enoxa-
parin. Results: The budget impact (per year, same during the 3 years) of the use 
of only bemiparin resulted in a 13% of cost savings related to the current scenario 
and in a 17% of cost savings compared with only enoxaparin. Enoxaparin compared 
with the current scenario resulted in a 4% of incremental costs. Bemiparin repre-
sents savings of around € 700,000 per year compared with current treatment and 
around € 900,000 per year when it is used in a 100% of patients instead of enoxa-
parin. ConClusions: The budget impact analysis may be important when decid-
ing which LWMH to use for the treatment of VTE. This analysis provides evidence 
reinforcing the use of bemiparin as the LMWH of choice, because its use resulted in 
a budget impact reduction for the Spanish National Health System.
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PresCriPtion algorithMs: iMPaCt on statins
Buigues-Pastor L1, SÁnchez-Chorro JL2, MÉndez-Valera P1, MuÑoz-FernÁndez JI2
1Valencian Regional Government - Spain, Valencia, Spain, 2Extremadura’s Regional Government - 
Spain, Mérida, Spain
intRoduCtion: Statin therapy has proved effective in reducing cardiovascular 
morbidity and mortality. However, the cost of a defined daily dose (DDD) differs 
from a statin to another, being generally atorvastatin and simvastatin the best 
choice under the criteria of cost effectiveness. objeCtives: To assess the conse-
quences in terms of outpatient pharmaceutical expenditure and DDD prescribed, 
that accounted due to the introduction of “prescription algorithms” into the elec-
tronic prescribing tool for physicians. Check whether the prescription of statins has 
been moved towards cost effective alternatives. Methods: Cross-sectional study 
outpatient management were obtained by micro-costing. Costs were expressed in 
2015 prices and exchange rate was $1.00USD= 3.00BRL. Results: It was estimated 
60,279 patients with VTE in the entire private health system, which by switching to 
rivaroxaban, would result in overall $38.4 million savings. From the single health plan 
perspective, an average of 540, 56 and 9 patients with VTE are expected for the three 
profiles and would result in savings of $343.0, $35.8 and $5.6 thousands, respectively 
in big, medium and small size plans. Cost savings are mainly associated with shorter 
length of stay with rivaroxaban. Robustness of the model was tested in deterministic 
univariate sensitivity analysis in which results remained cost saving. ConClusions: 
Rivaroxaban has potential to yield savings for VTE treatment under Brazilian private 
system perspective.
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iMPaCt on italian national health serViCe exPenditure for the 
treatMent of Venous throMboeMbolisM with riVaroxaban
Roggeri A1, Roggeri DP1, Pengo V2
1ProCure Solutions, Nembro (BG), Italy, 2University Hospital Padova, Padova, Italy
objeCtives: Venous thromboembolism (VTE), including deep vein thrombosis 
(DVT) and pulmonary embolism (PE) represents the third most common cardio-
vascular pathology after acute coronary syndrome and stroke. Rivaroxaban, a novel 
oral simplified therapy approved for treatment of DVT and PE leads to reduction in 
thromboembolic and haemorrhagic events and does not need laboratory monitor-
ing. This study aims to evaluate the economic impact of the use of rivaroxaban for 
preventing DVT and PE in Italy. Methods: The present analysis estimates clinical 
outcomes and economic consequences of the substitution of rivaroxaban versus 
standard therapy [(low molecular weight heparin (LMWH) + vitamin K antagonists 
(VKA)] for the treatment of VTE. In the analysis we considered a progressive replace-
ment of LMWH/VKA with rivaroxaban (22%, 25%, and 27% in DVT and 12%, 16%, and 
20% in PE) over a three years time horizon. Clinical outcomes with the two alterna-
tive treatments available were estimated using data from the EINSTEIN studies, 
which directly compare rivaroxaban with LMWH/VKA. Direct healthcare costs have 
been estimated in the perspective of Italian National Health Service (INHS) (drugs, 
hospitalizations, visits and laboratory monitoring). Results: The replacement 
of LMWH/VKA with rivaroxaban in DVT and PE is associated with a reduction in 
events (recurrent symptomatic thromboembolism, major bleeding, vascular events 
and mortality). This reduction, together with the absence of laboratory monitor-
ing costs for patients treated with rivaroxaban leads to an expenditure saving for 
the INHS in the first three years of about € 8.4 million in DVT and € 3.2 million 
in PE. ConClusions: The simplified therapy with rivaroxaban, as confirmed by 
the clinical trials, may provide significant clinical advantages in terms of avoided 
events and related costs. Moreover, without the need for laboratory monitoring, the 
increase in pharmacological expenditure is completely compensated leading overall 
to significant cost savings to the INHS.
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budget iMPaCt analysis of triPliaM for the treatMent of 
hyPertension in italy
Lanati EP, Orlando VL
MA Provider Srl, Milano, Italy
objeCtives: The objective of this study was to perform a Budget Impact Analysis 
(BIA) assessing the introduction of Tripliam for the treatment of hypertension into 
the Italian market. Tripliam is the first and only available single-tablet triple com-
bination antihypertensive therapy containing perindopril, amlodipine and inda-
pamide, in line with current evidence-based recommendations for the treatment 
and management of hypertension. Methods: The BIA compared two different 
scenarios: Scenario 1 without a triple fixed combination therapy vs. Scenario 2 with 
the introduction of Tripliam. Population data were obtained from a Local Project 
Database by Cegedim. The time horizon considered was 3 years from the introduc-
tion of Tripliam. Total number of patients in each of the 3 years was the same for the 
two Scenarios, because the model allows only the switch of patients from the dual 
or triple combinations to the fixed dose treatment with Tripliam. The perspective 
of the Italian National Healthcare Service was considered. Results: The study 
showed that the introduction of Tripliam leads to a reduction in the quantity of pills 
taken by patients (7.014.644, 8.743.882 and 10.127.208 in Scenario 1 and 6.469.258, 
7.762.951 and 8.657.031 in Scenario 2, respectively in year 1, 2 and 3). With a cost of 
11,26 € /month, the introduction of Tripliam generates a very limited incremental 
costs in year 1 and 2 (respectively 2.977 € and 501 € ) and a saving in the third year 
(3.478 € ) over the total expenditure of 45.7, 51.9 and 56.7 respectively in year 1, 2 
and 3 in the two scenarios. ConClusions: The present study indicates that the 
introduction of Tripliam does not imply additional treatment costs, but improves 
the adherence to the therapy, thanks to the reduction in the number of pills taken 
by patients. Better adherence is also linked to a reduction in the number of hospi-
talizations and related costs.
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budget-iMPaCt-analysis of iron treatMent using intraVenous ferriC 
CarboxyMaltose in Patients with ChroniC heart failure and iron 
defiCienCy in austria
Ressl S, Walter E, Bauer M
Institute for Pharmaeconomic Research, Vienna, Austria
objeCtives: Iron deficiency (ID) is highly prevalent in chronic heart failure (CHF) 
patients and imposes a significant disease burden for CHF patients with enormous 
impact on their outcome. CHF with ID is a major reason for hospitalization and 
represents important costs for the national health care budget in Austria. Yet, only 
a small percentage of CHF patients with ID are diagnosed. Thus, the objective of 
this analysis is the evaluation of the cost saving potential through an increased 
use of intravenous iron therapy with ferric carboxymaltose (FCM) based on clinical 
trial evidence. Methods: A budget impact analysis (BIA) with a four-year’s time 
horizon was developed from the health insurance perspective. The main objec-
